Gilead Sciences, Inc. $GILD Shares Bought by Global Retirement Partners LLC

Global Retirement Partners LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 80.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,281 shares of the biopharmaceutical company’s stock after buying an additional 14,414 shares during the quarter. Global Retirement Partners LLC’s holdings in Gilead Sciences were worth $3,962,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Baron Silver Stevens Financial Advisors LLC increased its holdings in Gilead Sciences by 3.4% in the 4th quarter. Baron Silver Stevens Financial Advisors LLC now owns 7,260 shares of the biopharmaceutical company’s stock worth $891,000 after buying an additional 236 shares during the period. CWS Financial Advisors LLC increased its holdings in Gilead Sciences by 22.4% in the 4th quarter. CWS Financial Advisors LLC now owns 3,904 shares of the biopharmaceutical company’s stock worth $479,000 after buying an additional 714 shares during the period. Fi3 FINANCIAL ADVISORS LLC increased its holdings in Gilead Sciences by 11.9% in the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 2,549 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 271 shares during the period. Sierra Summit Advisors LLC increased its holdings in Gilead Sciences by 2.3% in the 4th quarter. Sierra Summit Advisors LLC now owns 24,153 shares of the biopharmaceutical company’s stock worth $2,965,000 after buying an additional 554 shares during the period. Finally, MJP Associates Inc. ADV increased its holdings in Gilead Sciences by 25.0% in the 4th quarter. MJP Associates Inc. ADV now owns 2,661 shares of the biopharmaceutical company’s stock worth $327,000 after buying an additional 532 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to Hepcludex (bulevirtide-gmod) for chronic hepatitis delta virus (HDV), making it the first and only approved treatment in the U.S. for this rare and serious liver disease. That opens a new commercial opportunity in a high-unmet-need market. Article Title
• Positive Sentiment: Gilead also received a CHMP positive opinion in Europe for Trodelvy in first-line metastatic triple-negative breast cancer, supporting broader international adoption of one of its key oncology products. Article Title
• Positive Sentiment: Gilead completed its Tubulis acquisition, adding next-generation antibody-drug conjugate assets and strengthening its oncology pipeline. Article Title
• Positive Sentiment: Analysts at Zacks Research raised near-term EPS estimates for some periods and maintained strong longer-term profit expectations, which can support investor confidence in Gilead’s earnings outlook. Article Title
• Neutral Sentiment: Gilead announced a renewed collaboration with the World Health Organization to help eliminate visceral leishmaniasis, a public-health initiative that is strategically positive but likely not an immediate stock driver. Article Title
• Negative Sentiment: Some analyst updates trimmed certain 2026–2028 earnings estimates, which may temper enthusiasm around the stock’s longer-term growth rate, even as recent product news remains favorable. Article Title

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,000 shares of company stock worth $8,523,570 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Up 3.0%

Shares of NASDAQ:GILD opened at $134.36 on Friday. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The firm has a market capitalization of $166.82 billion, a price-to-earnings ratio of 18.31 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The business’s 50 day moving average price is $136.27 and its 200-day moving average price is $133.65.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the firm posted $1.81 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Analyst Ratings Changes

GILD has been the topic of several research reports. Scotiabank increased their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. Bank of America set a $162.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, February 11th. Wolfe Research upped their price objective on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Leerink Partners lowered their price objective on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Finally, Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.